AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
CLADRIBINE
8 registrations across 3 African markets— 4 active
Markets with CLADRIBINE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| MAVENCLAD 10 mg | 🇿🇦South Africa | Merck (Pty) Ltd | active | Oct 2027 |
| MAVENCLAD Comprimé / 10mg | 🇹🇳Tunisia | MERCK EUROPE B.V | expired | Oct 2021 |
| MAVENCLAD Comprimé / 10mg | 🇹🇳Tunisia | MERCK EUROPE B.V | expired | Oct 2021 |
| MAVENCLAD Comprimé / 10mg | 🇹🇳Tunisia | MERCK EUROPE B.V | expired | Oct 2021 |
| LITAK Solution injectable / 10 mg (2mg/ml) | 🇹🇳Tunisia | LIPOMED AG | expired | Feb 2015 |
| LITAK 10 | 🇿🇦South Africa | Key Oncologics (Pty) Ltd | active | Jan 1900 |
| LITAK 10 SOLUTION POUR INJECTION SOUS-CUTANEE OU PERFUSION IV | 🇲🇦Morocco | — | active | — |
| LITAK 10 SOLUTION POUR INJECTION SOUS-CUTANEE OU PERFUSION IV | 🇲🇦Morocco | — | active | — |
CLADRIBINE in Africa — Regulatory Overview
CLADRIBINE is registered across 3 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tunisia, Morocco, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 4 (50%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.